Weiler Kathy Johnson 4

What Happened
Kathy Weiler Johnson, a director of Axogen, had restricted stock units (RSUs) vest on June 19, 2026 and converted into 14,150 shares of Axogen common stock. The Form 4 shows the acquisition as an exercise/conversion of a derivative at $0.00 per share (no cash paid). The underlying annual equity grant was valued at $150,000 at grant date.

Key Details

• Transaction date: June 19, 2026; Form 4 filed June 23, 2026 (timely filing given weekend).
• Reported transaction: 14,150 shares acquired via conversion/vesting of RSUs; exercise price $0.00; reported value $0 (cost basis via vesting).
• Footnotes: F1–F3 confirm these were RSUs that vested, each RSU equals one share, and this was the director’s annual equity grant based on a $150,000 valuation that vested on the one-year anniversary.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: M (exercise or conversion of a derivative) — here used for RSU conversion/vesting, not a cash purchase or sale.

Context: This was a routine director equity vesting (award converting to shares), not an open‑market purchase or sale. Such vesting is common compensation for board service and does not necessarily signal a change in insider sentiment.